Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 170

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 170
---
 our business by, among other methods, seeking and maintaining
patents, where available, that are intended to cover our product candidates (and products derived therefrom), compositions and formulations,
their methods of use and processes for their manufacture and any other inventions that are commercially important to the development of
our business. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and
maintain our proprietary and competitive position.

| 85 |

We have developed a strong
intellectual property base globally, comprising patents, know-how, and trade secrets. Currently, we have 53 granted patents, seven applications
in process, in each case covering all major world markets, and 14 separate patent families covering all major regions. We continue to
strengthen our patent portfolio by strategically submitting new patents and divisional patent applications based on our active research
and development activities. Central to our business are our three intellectual property technologies that are designed to enable the targeted
delivery, i.e. right place, and controlled sustained release, i.e. right time, of existing therapeutic drugs. These technologies have
broad applications in multiple therapeutic areas and offer the potential to create multiple revenue opportunities.

Patent rights have been granted
in all the major world markets, including Europe, the United States and Japan, or the Key Markets. The granted patents and pending patent
applications in our patent families are owned solely by us, co-owned with other parties or in-licensed to us. These include patents related
to methods of use of eRapa, tolimidone and MTX110 as well as patents covering sustained release drug delivery, nano-inclusion technology
and nanoparticle technology.

The term of individual patents depends upon the
legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is
20 years from the filing date of a non-provisional patent application. In the United States, a patent’s term may, in certain cases,
be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark
Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent.

The term of a United States
patent that covers a drug, biological product or medical device approved pursuant to a pre-market approval may also be eligible for patent
term extension when FDA approval is granted, provided that certain statutory and regulatory requirements